Charles River Laboratories © 2023 Charles River Laboratories International, Inc. Safe Harbor Statement 2 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indica ...

Market Demand and Competition - A reduction in demand for drug R&D expenditures by pharmaceutical and biotechnology companies could adversely affect the company's business[80] - The outsourcing trend in non-clinical research support activities is expected to continue, but any decrease could impair the company's growth[88] - The company faces significant competition from other non-clinical drug development partners and internal departments of larger clients, which may have greater resources[89] - New technologies in biomedical research may reduce demand for traditional products and services, impacting sales[92] - The outsourcing trend in non-clinical drug discovery and development may decrease, which could impair the company's growth and sales[88] Regulatory and Compliance Challenges - The company's CDMO operations depend significantly on regulatory approvals; delays or failures in these approvals could materially impact revenue and profitability[80] - Changes in government regulations or healthcare reforms may decrease the demand for the company's services, impacting R&D expenditures by clients[82] - The FDA Modernization Act 2.0 may lead to a gradual reduction in the use of animals in testing, potentially adversely affecting the company's business[82] - The company emphasizes the importance of data integrity and has established global governance teams to ensure compliance with regulatory standards[96] - The company has a dedicated group managing global regulatory compliance programs to meet various national and international laws[96] Financial Performance and Revenue Sources - Revenue from clients at academic institutions and research laboratories is partially dependent on government funding, which is difficult to forecast and may be adversely affected by budget proposals[82] - The financial condition and operational results may be adversely affected if the products manufactured for customers do not gain market acceptance[82] - A significant decrease in drug R&D expenditures by clients could adversely affect the company’s business and profitability[80] - A significant portion of the company's revenue is derived from international operations, which are expected to continue accounting for a substantial percentage of total revenue[59] - The company’s revenue is partially dependent on government funding for R&D, which is subject to political uncertainties and could affect client purchasing decisions[82] Operational Risks and Challenges - Contaminations in animal populations could damage inventory and harm the company's reputation, leading to decreased sales and additional costs[85] - The company relies on third-party suppliers for raw materials, and any delays or failures in supply could materially impact operations and financial condition[72] - The supply of non-human primates, which accounts for approximately 60% of the U.S. market, has been constrained due to geopolitical issues and health-related disruptions[78] - The ongoing conflict between the Russian Federation and Ukraine has resulted in negative impacts on the global economy, affecting supply chains and increasing costs for materials and transportation[63] - The COVID-19 pandemic has caused disruptions in operations, including temporary closures of facilities and interruptions in global supply chains, which may continue to affect financial performance[66] Strategic Growth and Development - The company is focused on developing and marketing new services and products to meet client needs, but faces challenges in identifying and commercializing new technologies[93] - The company aims to be the preferred strategic non-clinical drug development partner, focusing on an integrated portfolio of drug discovery and non-clinical development products and services[38] - The company has expanded its service capabilities into the high-growth sector of cell and gene therapy, aiming to deliver integrated solutions to accelerate development and manufacturing[50] - Recent acquisitions, including Distributed Bio and Explora BioLabs, are part of the company's growth strategy to enhance its portfolio and geographic footprint[50] - The company continues to expand its portfolio in key therapeutic areas, aligning with clients' drug discovery and development needs, particularly in small molecules and biologics[39] Leadership and Corporate Governance - Corporate governance standards are adhered to, with nine of eleven board members being independent, ensuring accountability and transparency[100] - The executive team has extensive experience, with key members holding significant positions in the company for many years, contributing to strategic growth[101] - The company has a strong leadership team with extensive experience in various sectors, enhancing its strategic vision and operational growth[104] - The executive team is focused on long-term growth and success across multiple business segments[104] - The company emphasizes collaboration among its business units to develop and implement effective business strategies[104]

Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET | --- | |---------------------------------------------------------------------------------------------------| | | | Company Participants | | Todd Spencer - VP, IR James Foster - Chairman, President & CEO Flavia Pease - Corporate EVP & CFO | | Conference Call Participants | | Eric Coldwell - Baird | | Derik De Bruin - Bank of America | | Sandy Draper - Guggenheim | | David Windley - Jefferie ...

3Q 2022 Results November 2, 2022 Charles River Laboratories EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc. charles river Safe Harbor Statement 2 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2022 Earnings Conference Call August 3, 2022 9:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster – Chairman, President and Chief Executive Officer Flavia Pease – Corporate Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin – Bank of America Eric Coldwell – Baird Dave Windley – Jefferies Sandy Draper – Guggenheim Elizabeth Anderson – Evercore Christine Rains – Wil ...

2Q 2022 Results August 3, 2022 Charles River Laboratories EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc. Safe Harbor Statement 2 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" ...

1Q 2022 Results May 4, 2022 Charles River Laboratories EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc. charles river Safe Harbor Statement 2 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," an ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2022 Earnings Conference Call May 4, 2022 9:30 AM ET | --- | |--------------------------------------------| | | | Company Participants | | Todd Spencer - VP, IR | | James Foster - Chairman, President and CEO | | Flavia Pease - Interim CFO and EVP | | David Smith - EVP and CFO | | Conference Call Participants | | Eric Coldwell - Baird | | Jacob Johnson - Stephens | | Elizabeth Anderson - Evercore ISI | | Dave Windley - Jefferies | | Casey Woodring ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2021 Earnings Conference Call February 16, 2022 8:30 AM ET Company Participants Todd Spencer - Corporate Vice President, Investor Relations James Foster - Chairman, President and Chief Executive Officer David Smith - Corporate Executive Vice President and Chief Financial Officer Conference Call Participants Derik de Bruin - Bank of America Merrill Lynch John Kreger - William Blair Tycho Peterson - J.P. Morgan David Windley - Jefferies Patrick Donn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 25, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 charles river CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Securities registered pursuant to S ...